Chronic Hepatitis B Clinical Trial
Official title:
Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B
Verified date | September 2015 |
Source | Abivax S.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is an open-label, randomized, comparative, multicenter clinical trial. The purpose of this study is to assess the efficacy of ABX203, a new chronic hepatitis B therapeutic vaccine administered as an adjunct therapy to nucleos(t)ide analogs (NUCs), in maintaining control of Hepatitis B disease after cessation of treatment with NUCs in subjects with HBeAg negative chronic Hepatitis B.
Status | Completed |
Enrollment | 261 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female subject between 18 and 65 years of age at the time of randomization. - Must be HBeAg negative and anti-HBe Abs positive for at least 1 year prior to screening and at screening. - Has HBV DNA < 40 IU/mL for at least 1 year prior to screening and at screening - Has both ALT and AST levels = ULN for at least 1 year prior to screening and at screening. - Must be HBsAg positive at screening. - Has been treated with NUCs for at least 2 years prior to screening. - Has not been treated with PEG-IFN or IFN for at least 1 year prior to screening. - For all females, must have a negative serum pregnancy test at screening. For female of childbearing potential, must have been using adequate contraception and must agree to continue to use it during all study period and for 6 months after completion of the study product administration. - Has provided written informed consent. Exclusion Criteria: - Has elevated blood levels of alpha-fetoprotein (AFP) (> 500 ng/mL). - Has cirrhosis, defined as - platelet count < 150,000/mm3, with esophageal varices on imaging and spleen size > 12, or - liver stiffness of 11 kilopascal [kPa] as measured by elastography using FibroScan® or .an AST to Platelet Ratio Index (APRI) > 2). - Has hepatocellular carcinoma (HCC) (diagnosed by ultrasonography). - Has liver decompensation (albumin < 3.5 g/dL and bilirubin =1.3 mg/dL). - Is Hepatitis C virus (HCV) Ab positive at screening. - Is Hepatitis delta virus (HDV) Ab positive at screening. - Is Human Immunodeficiency Virus (HIV) Ab positive at screening. - Has an immune suppressive disorder or treatment with immunosuppressive drugs. - Has been treated with corticosteroids within 12 weeks prior to the first administration of study product, with the exception of topical or inhaled corticosteroids. - Has been treated with rituximab. - Has other hepatic diseases of different etiology (such as auto-immune hepatitis, toxic hepatitis, Wilson disease, alcoholic or hemochromatosis). - Has a history of allergic disease or reactions likely to be exacerbated by any component of the study products. - Has a history of a substance abuse (drug or alcohol) problem within the previous 3 years. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Prince Alfred Hospital | Camperdown | |
Australia | Monash Medical Centre Clayton | Clayton | |
Australia | St Vincent's Hospital Melbourne | Fitzroy | |
Australia | Austin Hospital | Heidelberg | |
Australia | Liverpool Hospital | Liverpool | |
Australia | The Alfred Hospital | Melbourne | |
Australia | Royal Melbourne Hospital | Parkville | |
Australia | Royal Perth Hospital | Perth | |
Australia | Westmead Hospital | Westmead | |
New Zealand | Auckland City Hospital | Auckland | |
New Zealand | Waikato Hospital | Hamilton West | |
New Zealand | Wellington Hospital | Wellington |
Lead Sponsor | Collaborator |
---|---|
Abivax S.A. |
Australia, New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of subjects with viral load < 40 IU/mL at Week 48. | Week 48 | ||
Secondary | Clinical response defined as changes in viral load, liver function, time to relapse | Week 48 and Week 96 | ||
Secondary | Immune response defined as T-cell response by ICS (CD4 and CD8 to HBcAg and HBsAg) | Week 48 | ||
Secondary | Safety assessment will be conducted throughout the study and will include physical examinations, vital signs, clinical laboratory évaluations, and the recording of AEs | Participants will be followed for the duration of their study participation up to 96 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04496882 -
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
|
Phase 4 | |
Completed |
NCT04083716 -
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT03038802 -
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
|
Phase 1/Phase 2 | |
Completed |
NCT05310487 -
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT06070051 -
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
|
Phase 1 | |
Terminated |
NCT05001022 -
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
|
Phase 1 | |
Recruiting |
NCT04139850 -
The Establishment of Korean Hepatitis B Patients Cohort
|
||
Recruiting |
NCT05343481 -
Efficacy of VTP-300 in Chronic Hepatitis B Infection
|
Phase 2 | |
Not yet recruiting |
NCT05490836 -
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
|
N/A | |
Recruiting |
NCT04543565 -
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
|
Phase 3 | |
Active, not recruiting |
NCT02894918 -
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
|
Phase 4 | |
Not yet recruiting |
NCT02793791 -
Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients
|
N/A | |
Recruiting |
NCT02287857 -
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
|
N/A | |
Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
Recruiting |
NCT01491295 -
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
|
Phase 4 | |
Terminated |
NCT01872988 -
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
|
Phase 3 | |
Recruiting |
NCT01487876 -
Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
|
Phase 2 | |
Completed |
NCT01531166 -
A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon
|
N/A | |
Not yet recruiting |
NCT01436539 -
Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients
|
Phase 4 | |
Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A |